Consejo Nacional de Salud

46 Engert, Franklin J, Theodor Eich H, Brillant C,
Sehlen S, Cartoni C, Herrmann R, Pfreundschuh
M, Sieber M, Tesch H, Franke, A, Koch P, de Wit
M, Paulus U, Hasenclever D, Loeffler M, Mu¨ller
R-P, Konrad Mu¨ller-Hermelink H, Du¨hmke H,
Diehl V, Two Cycles of Doxorubicin, Bleomycin,
Vinblastine, and Dacarbazine Plus Extended-
Field Radiotherapy Is Superior to Radiotherapy
Alone in Early Favorable Hodgkin’s Lymphoma:
Final Results of the GHSG HD7 Trial, J Clin Oncol
25:3495-3502
47 Brambilla L, Miedico A, Ferrucci S, Romanelli A,
Brambati M, Vinci M, Tedeschi L, Boneschi V,
Combination of vinblastine and bleomycin as first
line therapy in advanced classic Kaposi’s sarcoma,
JEADV 2006, 20 , 1090–1094
48 Caron J M, Herwood M, Vinblastine, a Chemotherapeutic
Drug Inhibits Palmitoylation of Tubulin
in Human Leukemic Lymphocytes, Chemotherapy
2007;53:51–58, DOI: 10.1159/000098419
49 Young S D, Whissell M, Noble J CS, Cano P, Lopez
P G, Germond C J, Phase II ClinicalTrial Results
InvolvingTreatment with Low-Dose Daily Oral
Cyclophosphamide Weekly Vinblastine, and Rofecoxibin
Patients with Advanced Solid Tumors,
Clin Cancer Res 2006;12(10)May 15, 2006 3092,
www.aacrjournals.org
50 Thomas D A, Sarris A H, Cortes D J, Faderl S, O’Brien
S, Giles F J, Garcia-ero G, Rodriguez M A, Cabanillas
F, Kantarjian H, Phase II Study of Sphingosomal
Vincristine in Patients with Recurrent or Refractory
Adult Acute Lymphocytic Leukemia, CANCER January
1, 2006 / Volume 106 / Number 1
51 Dann E J, Bar-Shalom R, Tamir A, Haim N, Ben-
Shachar M, Avivi I, Zuckerman T, Kirschbaum M,
Goor O, Libster D, Rowe J M, Epelbaum R, Riskadapted
BEACOPP regimen can reduce the cumulative
dose of chemotherapy for standard and
high-risk Hodgkin lymphoma with no impairment
of outcome, BLOOD, 1 February 2007 _ Volume
109, Number 3 From Www.Bloodjournal.Org By
On November 19, 2008.
52 Micallef I N M, Kahl B S, Maurer MJ, Dogan
A, Ansell S M, Colgan J P, Geyer S, Inwards D
J, White W L, Habermann T M, A Pilot Study of
Epratuzumab and Rituximab in Combination With
Cyclophosphamide, Doxorubicin, Vincristine, and
Prednisone Chemotherapy in Patients With Previously
Untreated, Diffuse Large B-Cell Lymphoma,
CANCER December 15, 2006 / Volume 107 /
Number 12, 2828-32
53 Shin H-J, Chung J S, Lee J J, Sohn S K, Jin Choi Y,
Kim J-K, Yang D-H, Kim H-J, Kim J-G, Don Joo Y,
Lee W S, Sohn Ch, Lee E Y, Cho G J, Treatment
Outcomes with CHOP Chemotherapy in Adult Patients
with Hemophagocytic Lymphohistiocytosis,
J Korean Med Sci 2008; 23: 439-44
54 Gandhi L, Harding M W, Neubauer M, Langer C
J, Moore M, Ross H J, Johnson B E, Lynch T J, A
Phase II Study of the Safety and Efficacy of the
Multidrug Resistance Inhibitor VX-710 Combined
With Doxorubicin and Vincristine in Patients With
Recurrent Small Cell Lung Cancer, CANCER
March 1, 2007 / Volume 109 / Number 5
55 Tsukamoto T, Yonese J, Ohkubo Y, Fukui
I,Department of Urology, Cancer Institute Hospital,
Tokyo, Japan Phase I/II Study of a Combined
Gemcitabine,
Etoposide, and Cisplatin Chemotherapy Regimen
for Metastatic Urothelial Carcinoma, CANCER
June 1, 2006 / Volume 106 / Number 11, 2363–8.
American Cancer Society, DOI 10.1002/cncr.21897
Published online 28 April 2006 in Wiley
InterScience (www.interscience.wiley.com).
56 Miyazaki M, Fujiwara Y, Oguri T, Takahashi T,
Ohune T, Sumiyoshi H, Kohno N, Egorin M J,
Clinical Pharmacological Profile Of Etoposide In
Elderly Patients With Lung Cancer, Asia–Pacific
Journal of Clinical Oncology 2005; 1: 92–97
GRUPO L | Agentes antineoplásicos e inmunomoduladores
393
L